May 16, 2025

3 things you missed in government this week

ADA News is providing a roundup of happenings in government you may have missed.

ADA News

May 16, 2025

vNOTES Speeds Bowel, Work Recovery After Hysterectomy

A prospective study found that patients who underwent vNOTES hysterectomy recovered bowel function and returned to work faster than those who had traditional laparoscopic surgery.

Conexiant

May 16, 2025

Semaglutide Use Linked to Fewer Foot Ulcers

A large-scale study found semaglutide use was associated with reduced risks of amputation, chronic pain, and wound complications in patients with diabetes-related foot ulcers.

Conexiant

May 16, 2025

Upadacitinib Maintains UC Remission Through 96 Weeks

A 3-year study found that most patients with moderate to severe ulcerative colitis who responded to initial upadacitinib treatment stayed in remission through 96 weeks, with manageable side effects and consistent results across dosage groups.

Conexiant

May 15, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical ...

The ASCO Post

May 14, 2025

Mind the Gap: Could GLP-1 RAs Bridge Body and Brain Treatment?

A systematic review reveals that GLP-1 receptor agonists not only address psychotropic-induced metabolic disorders but also may positively impact mental wellbeing.

Conexiant

May 13, 2025

GLP-1s May Protect Against Obesity-Related Cancer

First-generation GLP-1 receptor agonists provide comparable protection against obesity-related cancers as bariatric surgery.

Conexiant

May 13, 2025

Appendectomy Cuts UC Relapse Rates, Study

Appendicectomy may significantly reduce relapse rates within 1.

Conexiant

May 13, 2025

Tirzepatide Tops Semaglutide for Weight Loss

In the SURMOUNT-5 trial, tirzepatide led to a 20.2% mean weight loss in adults with obesity—significantly more than the 13.7% achieved with semaglutide.

Conexiant